Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00176605 · ClinicalTrials.gov registry record · Phase 2
Phase II Metronomic Dosing, Etoposide, Cyclophosphamide, D0 Prostate Cancer
A Phase 2 study, sponsored by Rutgers, The State University of New Jersey.
- Completed
- Registry status
- Phase 2
- Development phase
- 15
- Enrollment target
NCT00176605 is a Phase 2 study that has completed, run by Rutgers, The State University of New Jersey. The registered enrollment target is 15 participants.
The verdict
NCT00176605, a Phase 2 study, has completed, sponsored by Rutgers, The State University of New Jersey.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 15 participants
- Enrollment target
Study Summary
Based on data supporting the use of cyclophosphamide and etoposide both as single agents in combination and a Phase I study showing acceptable toxicity with a chronic dosing regimen, we propose a Phase II clinical trial. This protocol establishes a model that will test the hypothesis that the use of etoposide and cyclophosphamide early in the course of prostate cancer progression, when fewer tumor cells are present, will have greater anti-tumor activity. We plan to treat patients with stage D0 prostate cancer to assess toxicity and anti-tumor activity.
Interventions
- DRUG Cyclophosphamide
- DRUG Etoposide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2005-05 |
| Est. Completion | 2008-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00176605
The ClinicalTrials.gov registry entry for NCT00176605 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Rutgers, The State University of New Jersey, which has 413 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Cyclophosphamide is the first listed.
NCT00176605 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00176605 about?
NCT00176605 is a clinical study titled "Phase II Metronomic Dosing, Etoposide, Cyclophosphamide, D0 Prostate Cancer". Based on data supporting the use of cyclophosphamide and etoposide both as single agents in combination and a Phase I study showing acceptable toxicity with a chronic dosing regimen, we propose a Phase II clinical trial. This protocol establishes a model that will test the hypothesis that the use of...
What is the current status of trial NCT00176605?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 15 participants. The study started on 2005-05. Estimated completion is 2008-10.
What interventions are being tested in trial NCT00176605?
The interventions under investigation include: Cyclophosphamide (DRUG), Etoposide (DRUG).
Who is sponsoring clinical trial NCT00176605?
This trial is sponsored by Rutgers, The State University of New Jersey, which has 413 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.